pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

634 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • IRA's Medicare out-of-pocket cap increased access to drugs, study finds
    Medication usage, particularly for the most expensive drugs, increased significantly shortly after the Medicare annual out-of-pocket cost cap took effect in January 2025, a study published in JAMA…
    Endpoints · 1mo ago↗ source
  • Prepping for peptides
    It wasn’t too many years ago when we were busy theorizing about the market opportunity for GLP-1 weight loss drugs. Now, the big question is the moneymaking potential for other peptides that might…
    Endpoints · 1mo ago↗ source
  • Pfizer CFO to depart; GSK wins approval for UTI drug
    Plus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋…
    Endpoints
← prev
page 11 of 26
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 1mo ago
↗ source
  • RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
    The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech. RA Capital and Forbion — partners on a coup…
    Endpoints · 1mo ago↗ source
  • Novocure’s electric fields therapy fails key glioblastoma study
    Novocure reported Thursday morning that its electric fields device combined with chemoradiation failed to extend glioblastoma patients' lives in a Phase 3 study, dampening the company's hopes of ex…
    Endpoints · 1mo ago↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    A healthcare asset and royalties holding company is bringing a long-acting oral medicine approach back to life, resurrecting a drug delivery platform that had accumulated more than $380 million in…
    Endpoints · 1mo ago↗ source
  • Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs
    → In preparation for potential new product launches, Moderna has selected Ester Banque as chief commercial officer and expanded the role of president Stephen Hoge. Banque was head of US operations…
    Endpoints · 1mo ago↗ source
  • Eli Lilly's TuneLab hits 100 members, adding Chai's AI models
    The leader behind TuneLab, Eli Lilly's first-of-its-kind AI initiative, had no idea what to expect when it launched. Lilly was trying something new by effectively offering biotechs free access to…
    Endpoints · 1mo ago↗ source
  • Antifungal from F2G, Shionogi succeeds in Phase 3 study
    F2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called…
    Endpoints · 1mo ago↗ source
  • Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
    More evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…
    Endpoints · 1mo ago↗ source
  • Biogen makes up to $1B deal for secretive anti-inflammatory biotech
    Biogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline. The startup, RayThera, debuted last ye…
    Endpoints · 1mo ago↗ source
  • FDA gives rejected drugs another chance in post-Makary era
    Did you receive a complete response letter in the past year? Now may be the time for a resubmission. In the wake of FDA Commissioner Marty Makary's departure last month, the agency has already ag…
    Endpoints · 1mo ago↗ source
  • FDA warns telehealth companies over compounded GLP-1s
    The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs. The let…
    Endpoints · 1mo ago↗ source
  • UK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy says
    The waiting list at a UK online pharmacy for Novo Nordisk’s Wegovy pill now stands at 30,000 people a week after approval, in a sign of dramatic demand for the weight loss drug among patients ...
    Endpoints · 1mo ago↗ source
  • Hackers claim they stole Novo Nordisk AI models, manufacturing recipes
    Novo Nordisk got robbed and is in the unenviable position of being extorted by the thieves. At stake, according to a group that has claimed responsibility for a cyberattack, are some of Novo's mo…
    Endpoints · 1mo ago↗ source
  • In second reversal, FDA gives uniQure a green light to seek accelerated approval
    Regulatory flexibility appears to be back on the FDA’s menu following the departures of Marty Makary and Vinay Prasad. At the center of the debate, once again, is the ...
    Endpoints · 1mo ago↗ source
  • Jazz turns to AbCellera for T cell engagers in up to $4.1B partnership
    For much of its first decade, Canadian antibody developer AbCellera signed partnership after partnership, securing 40 biopharma alliances that led to more than a dozen clinical-stage drug candidate…
    Endpoints · 1mo ago↗ source
  • Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophy
    A startup with operations in California and China has quietly begun tests of a genetic medicine that could restore dystrophin, the vital muscle protein that is broken or missing in people born with…
    Endpoints · 1mo ago↗ source
  • Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
    Triveni Bio announced a $65 million Series C after its second asset for eczema entered clinical studies last month. The Series C was co-led by Ascenta Capital and Janus Henderson Investors and in…
    Endpoints · 1mo ago↗ source
  • Migraine biotech Vedana Therapeutics makes its debut with $46M Series A
    Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments fo…
    Endpoints · 1mo ago↗ source
  • Health groups say HHS is trying to 'rush reinstatement' of ACIP
    A group of health organizations has accused HHS of trying to use a “self-created crisis” to “rush reinstatement” of the CDC’s frozen vaccine advisory panel. The committee and its recommendations…
    Endpoints · 1mo ago↗ source
  • B cell therapy maker Be Bio stops hemophilia trial
    Be Biopharma disclosed in a federal clinical trials listing that it has terminated its study of a hemophilia B therapy made by editing a patient’s own cells. It was one of ...
    Endpoints · 1mo ago↗ source
  • FDA raises no major red flags with Moderna's flu shot
    The FDA provided tepid support of Moderna’s flu vaccine ahead of an advisory meeting but, more importantly, didn't appear to raise any major concerns that could hinder its prospects. In briefing…
    Endpoints · 1mo ago↗ source
  • FDA greenlights Colorado's drug import proposal
    The FDA gave the go-ahead for Colorado to try importing cheaper drugs from Canada, but it remains to be seen how or when this would actually begin. In a letter Monday ...
    Endpoints · 1mo ago↗ source
  • Edgewise to advance heart drug into Phase 3 following mid-stage data update
    Edgewise Therapeutics has shared plans to advance its drug candidate for a genetic heart disease into a registrational study on the back of updated Phase 2 data. The biotech said Tuesday ...
    Endpoints · 1mo ago↗ source